Oculis has gained exclusive global rights to neuroprotective drug candidate for glaucoma through a licensing agreement with Accure Therapeutics. Oculis, a global ophthalmology company, announced on March 2, 2022 that it has formed a licensing agreement with Accure Therapeutics, a private translational neuroscience R&D company, granting Oculis exclusive global rights to develop and commercialize ACT-01, […]

Interleukin-2, a cytokine that helps the immune system fight disease, is an FDA-approved treatment, but it has been associated with selectivity, toxicity and dosing issues. Those shortcomings have inspired a wave of biotechs trying to create the next generation of IL-2 therapies. Now, Rice University researchers say they did so using beadlike implants. In a […]

Ampio Pharmaceuticals (NYSE American:AMPE), citing a significant impact from COVID-19 on its second confirmatory Phase 3 trial of Ampion for the treatment of severe osteoarthritis of the knee (OAK), hopes to meet with the FDA in the first half of 2022 to discuss a proposed modified intent-to-treat efficacy analysis for AP-013, its second pivotal trial. “We […]